A QSP PDE Model of Adc Transport and Kinetics in Agrowing or Shrinking Tumor

Read the full article See related articles

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

When a tumor is treated with an antibody-drug conjugate (ADC) complex biochemistry occurs in a domain--the tumor--whose size and structure are changing. Some parts of the tumor may be growing because tumor cells proliferate. Other parts may be stagnant, or nearly so, because the cells there have been damaged by the cytotoxin. Still others may be shrinking because the cells there have been killed by the cytotoxin and are being cleared. Chemical concentrations within the tumor, which influence kinetics and transport, change as the tumor grows or shrinks. Cell surface antigen, to which ADCs are designed to bind, is lost when cells are cleared and is freshly introduced when cells proliferate. For these reasons, and because shrinking the tumor by killing its cells is the purpose of ADC treatment, it is important in a quantitative systems pharmacology (QSP) approach to the problem to model the evolution of tumor size and structure over the course of ADC treatment. In this paper we present a partial differential equation (PDE) model of ADC transport and kinetics in a growing and shrinking Krogh cylinder tumor.

Article activity feed